KR102416279B1 - Ｆｓｈｒ의 조절제로서의 피라졸 화합물 및 이의 용도 - Google Patents
Ｆｓｈｒ의 조절제로서의 피라졸 화합물 및 이의 용도 Download PDFInfo
- Publication number
- KR102416279B1 KR102416279B1 KR1020177001959A KR20177001959A KR102416279B1 KR 102416279 B1 KR102416279 B1 KR 102416279B1 KR 1020177001959 A KR1020177001959 A KR 1020177001959A KR 20177001959 A KR20177001959 A KR 20177001959A KR 102416279 B1 KR102416279 B1 KR 102416279B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- optionally substituted
- methyl
- nitrogen
- sulfur
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2014/080519 | 2014-06-23 | ||
| PCT/CN2014/080519 WO2015196335A1 (en) | 2014-06-23 | 2014-06-23 | Pyrazole compounds as modulators of fshr and uses thereof |
| PCT/CN2014/094459 WO2015196759A1 (en) | 2014-06-23 | 2014-12-22 | Pyrazole compounds as modulators of fshr and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170033314A KR20170033314A (ko) | 2017-03-24 |
| KR102416279B1 true KR102416279B1 (ko) | 2022-07-01 |
Family
ID=54936412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177001959A Expired - Fee Related KR102416279B1 (ko) | 2014-06-23 | 2014-12-22 | Ｆｓｈｒ의 조절제로서의 피라졸 화합물 및 이의 용도 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10208055B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3157929B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6557331B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102416279B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN106573937B (cg-RX-API-DMAC7.html) |
| AU (3) | AU2014398875B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2955415A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3157929T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2972131T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX389867B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2752173C2 (cg-RX-API-DMAC7.html) |
| WO (2) | WO2015196335A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015196335A1 (en) * | 2014-06-23 | 2015-12-30 | Tocopherx, Inc. | Pyrazole compounds as modulators of fshr and uses thereof |
| CN106967076A (zh) * | 2017-03-30 | 2017-07-21 | 河南师范大学 | 一种具有6h‑二苯并吡喃结构化合物及其制备方法 |
| CN106866692A (zh) * | 2017-03-30 | 2017-06-20 | 毛阿龙 | 具有苯并1,4‑二氧杂环己二烯酮结构的fshr拮抗剂的制备方法 |
| CN106977523A (zh) * | 2017-03-30 | 2017-07-25 | 河南师范大学 | 具有苯基并四氢吡咯结构的fshr拮抗剂及其制备方法 |
| US11584763B2 (en) * | 2017-12-22 | 2023-02-21 | Hibercell, Inc. | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| KR102709804B1 (ko) * | 2018-05-03 | 2024-09-25 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 레티노이드-관련 희귀 수용체 감마(ＲＯＲγ)의 조절제로서 벤즈이미다졸 유도체 및 이의 약학적 용도 |
| TW202112784A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之𠳭唏并嘧啶衍生物 |
| CN113754678B (zh) * | 2020-06-02 | 2023-03-10 | 江苏恒瑞医药股份有限公司 | 二氢硫代色烯并吡唑类衍生物、其制备方法及其在医药上的应用 |
| CN115835863B (zh) * | 2020-07-09 | 2025-08-12 | 江苏恒瑞医药股份有限公司 | 氧杂氮杂双环类衍生物、其制备方法及其在医药上的应用 |
| JP2023536442A (ja) | 2020-07-29 | 2023-08-25 | 江蘇恒瑞医薬股▲ふん▼有限公司 | オキサアザスピロ環系誘導体、その調製方法及びその医薬的応用 |
| CA3235146A1 (en) | 2021-10-14 | 2023-04-20 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
| JP2025527759A (ja) * | 2022-08-26 | 2025-08-22 | セルマティクス インク． | Ｆｓｈｒの新規なモジュレータおよびその使用 |
| JP2025535050A (ja) * | 2022-10-05 | 2025-10-22 | ラディオネティクス オンコロジー，インク． | 卵胞刺激ホルモン受容体（ｆｓｈｒ）を標的とした治療薬およびその使用 |
| IL322905A (en) | 2023-03-08 | 2025-10-01 | Ferring Bv | Small molecule FSH receptor modulators |
| WO2024263803A2 (en) * | 2023-06-21 | 2024-12-26 | Celmatix Inc. | Novel modulators of fshr and uses thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003024936A1 (en) | 2001-09-19 | 2003-03-27 | Pharmacia Corporation | Substituted pyrazolo compounds for the treatment of inflammation |
| WO2008035356A2 (en) | 2006-09-20 | 2008-03-27 | Glenmark Pharmaceuticals Limited | Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| US20100216785A1 (en) | 2009-02-25 | 2010-08-26 | Neuroscienze Pharmaness S.C. A.R.L. | Pharmaceutical compositions |
| US20100215741A1 (en) * | 2009-02-25 | 2010-08-26 | Neuroscienze Pharmaness S.C. A.R.L. | Pharmaceutical compounds |
| WO2011058149A1 (en) * | 2009-11-13 | 2011-05-19 | Merck Serono S.A. | Tricyclic pyrazol amine derivatives |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8814586D0 (en) | 1988-06-20 | 1988-07-27 | Erba Carlo Spa | Tricyclic 3-oxo-propanenitrile derivatives & process for their preparation |
| EP1307193A1 (en) | 2000-07-27 | 2003-05-07 | Affymax Research Institute | Agonists of follicle stimulating hormone activity |
| US7622471B2 (en) | 2003-02-07 | 2009-11-24 | Daiichi Pharmaceutical Co., Ltd. | Pyrazole derivatives having a pyridazine and pyridine functionality |
| EP1879898A2 (en) * | 2005-05-12 | 2008-01-23 | Wyeth a Corporation of the State of Delaware | Pyrrolobenzodiazepines and heterocyclic carboxamide derivatives as follicle stimulating hormone receptor (fsh-r) antagonists |
| TWI461426B (zh) * | 2009-05-27 | 2014-11-21 | Merck Sharp & Dohme | （二氫）咪唑並異〔５，１－ａ〕喹啉類 |
| WO2013006308A2 (en) | 2011-07-01 | 2013-01-10 | Merck Patent Gmbh | Dihydropyrazoles |
| WO2013012848A1 (en) | 2011-07-18 | 2013-01-24 | Merck Patent Gmbh | Benzamides |
| WO2013106409A1 (en) | 2012-01-10 | 2013-07-18 | Merck Patent Gmbh | Benzamide derivatives as modulators of the follicle stimulating hormone |
| HK1201837A1 (en) | 2012-02-08 | 2015-09-11 | 默克专利有限公司 | Deuterated thiazolidinone analogues as agonists for follicle stimulating hormone receptor |
| KR102318498B1 (ko) | 2013-06-24 | 2021-10-27 | 메르크 파텐트 게엠베하 | Fshr의 조절인자로서의 피라졸 화합물 및 이의 용도 |
| WO2014209978A1 (en) | 2013-06-24 | 2014-12-31 | Merck Patent Gmbh | Imidazole compounds as modulators of fshr and uses thereof |
| WO2015196335A1 (en) | 2014-06-23 | 2015-12-30 | Tocopherx, Inc. | Pyrazole compounds as modulators of fshr and uses thereof |
-
2014
- 2014-06-23 WO PCT/CN2014/080519 patent/WO2015196335A1/en not_active Ceased
- 2014-12-22 US US15/321,249 patent/US10208055B2/en active Active
- 2014-12-22 CA CA2955415A patent/CA2955415A1/en active Pending
- 2014-12-22 WO PCT/CN2014/094459 patent/WO2015196759A1/en not_active Ceased
- 2014-12-22 MX MX2017000182A patent/MX389867B/es unknown
- 2014-12-22 JP JP2017519756A patent/JP6557331B2/ja not_active Expired - Fee Related
- 2014-12-22 ES ES14896199T patent/ES2972131T3/es active Active
- 2014-12-22 CN CN201480081442.1A patent/CN106573937B/zh not_active Expired - Fee Related
- 2014-12-22 AU AU2014398875A patent/AU2014398875B2/en not_active Ceased
- 2014-12-22 RU RU2017101829A patent/RU2752173C2/ru active
- 2014-12-22 KR KR1020177001959A patent/KR102416279B1/ko not_active Expired - Fee Related
- 2014-12-22 DK DK14896199.8T patent/DK3157929T3/da active
- 2014-12-22 EP EP14896199.8A patent/EP3157929B1/en active Active
-
2018
- 2018-12-21 US US16/229,119 patent/US10941152B2/en not_active Expired - Fee Related
-
2019
- 2019-07-11 JP JP2019129171A patent/JP2019196375A/ja active Pending
-
2020
- 2020-02-20 AU AU2020201240A patent/AU2020201240A1/en not_active Abandoned
- 2020-11-18 JP JP2020191715A patent/JP2021038245A/ja active Pending
-
2021
- 2021-01-05 US US17/141,621 patent/US20220402929A1/en not_active Abandoned
- 2021-07-09 AU AU2021204814A patent/AU2021204814B2/en not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003024936A1 (en) | 2001-09-19 | 2003-03-27 | Pharmacia Corporation | Substituted pyrazolo compounds for the treatment of inflammation |
| WO2008035356A2 (en) | 2006-09-20 | 2008-03-27 | Glenmark Pharmaceuticals Limited | Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| US20100216785A1 (en) | 2009-02-25 | 2010-08-26 | Neuroscienze Pharmaness S.C. A.R.L. | Pharmaceutical compositions |
| US20100215741A1 (en) * | 2009-02-25 | 2010-08-26 | Neuroscienze Pharmaness S.C. A.R.L. | Pharmaceutical compounds |
| WO2011058149A1 (en) * | 2009-11-13 | 2011-05-19 | Merck Serono S.A. | Tricyclic pyrazol amine derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014398875A1 (en) | 2017-02-02 |
| CN106573937B (zh) | 2022-02-11 |
| AU2014398875B2 (en) | 2019-11-21 |
| WO2015196759A1 (en) | 2015-12-30 |
| MX2017000182A (es) | 2017-06-30 |
| US20170253605A1 (en) | 2017-09-07 |
| US20220402929A1 (en) | 2022-12-22 |
| JP6557331B2 (ja) | 2019-08-07 |
| MX389867B (es) | 2025-03-20 |
| EP3157929B1 (en) | 2023-12-13 |
| AU2021204814A1 (en) | 2021-08-05 |
| RU2752173C2 (ru) | 2021-07-23 |
| US20190135823A1 (en) | 2019-05-09 |
| AU2021204814B2 (en) | 2023-07-20 |
| EP3157929A1 (en) | 2017-04-26 |
| US10941152B2 (en) | 2021-03-09 |
| KR20170033314A (ko) | 2017-03-24 |
| CA2955415A1 (en) | 2015-12-30 |
| AU2020201240A1 (en) | 2020-03-12 |
| RU2017101829A (ru) | 2018-07-27 |
| CN106573937A (zh) | 2017-04-19 |
| EP3157929A4 (en) | 2018-03-07 |
| ES2972131T3 (es) | 2024-06-11 |
| US10208055B2 (en) | 2019-02-19 |
| JP2017524733A (ja) | 2017-08-31 |
| JP2021038245A (ja) | 2021-03-11 |
| JP2019196375A (ja) | 2019-11-14 |
| RU2017101829A3 (cg-RX-API-DMAC7.html) | 2018-08-30 |
| WO2015196335A1 (en) | 2015-12-30 |
| DK3157929T3 (da) | 2024-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102416279B1 (ko) | Ｆｓｈｒ의 조절제로서의 피라졸 화합물 및 이의 용도 | |
| KR102318498B1 (ko) | Fshr의 조절인자로서의 피라졸 화합물 및 이의 용도 | |
| JP6523267B2 (ja) | Ｆｓｈｒの調節剤としてのイミダゾール化合物及びその使用 | |
| HK1218757B (zh) | 用作卵泡刺激素受体调节剂的吡唑化合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20250630 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| H13 | Ip right lapsed |
Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE Effective date: 20250630 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20250630 |